The data has just been presented at the scientific sessions of the’American Heart Association (AHA) 2025 A large cohort (over 63,000 patients) with type 2 diabetes shows that the use of GLP-1 receptor agonists (GLP-1 RA) and the adoption of a set of «healthy lifestyle» behaviours is associated with a marked reduction in major cardiovascular events - much more so than medication or lifestyle changes alone. For healthcare professionals, R&D managers and players in the ingredients and nutraceuticals industry, the message is clear: the synergy between treatment and lifestyle is becoming an essential lever..
Why does the study contrast slightly with what was known about GLP-1 and its receptor agonists?
What we knew
- Patients with type 2 diabetes are known to have a high cardiovascular risk.
- It has also been proven that GLP-1 agonists have a beneficial effect not only on blood sugar levels but also on the cardiovascular profile.
- Similarly, lifestyle habits (physical activity, diet, not smoking...) reduce the overall risk.
What this study adds
- It quantifies: in this cohort of 63,656 veterans, those taking a GLP-1 RA and adhering to at least six healthy lifestyle habits have seen a ~50 % reduction in the risk of a major cardio event compared with those in standard care + ≤3 healthy habits.
- Another key figure: membership of 8 healthy habits was associated with a ~63 % reduction in risk.
- The message is clear: medication increases when accompanied by behavioural changes.
Points to watch
- This is a observational study, This non-randomised study has not yet been published as a peer-review manuscript.
- The population is overwhelmingly male (≈94 %), with 82 % white, and they are veterans: this limits generalisation.
- The «6 or more healthy habits» scheme needs to be developed in more detail before it can be translated into recommendations.
What “healthy habits” means in this study
In the analysis, the lifestyle habits considered included :
- healthy eating,
- sufficient physical activity,
- non-smoking,
- restful sleep,
- no or moderate alcohol consumption,
- stress management,
- social connection and support,
- absence of opioid dependence.
In other words, a holistic approach (and not just one based on diet or exercise) is essential to this data.
Implications for the ingredients industry & B2B health
Here are a few angles to consider.
1. Product positioning
If you are working on ingredients or formulations targeting metabolism, weight management or cardiometabolic health: this type of data reinforces the need to include «lifestyle + pharmacology» or «complementary to drug treatment» claims. On the other hand: don't claim that your ingredient alone replaces medication (that would be unrealistic). Hypothesis to be validated: are your targets (R&D, medical affairs, innovation managers) aware of this synergy?
2. Content strategy / healthcare education
Communicating on «treatment + healthy lifestyle = better reduction in cardio risk» can open up new formats: webinars, infographics, workshops for decision-makers (R&D, KAM, prescribers). The “optimisation of the patient/production trajectory” angle becomes relevant. A sceptical investor might say, “Yes, but can these habits be sold as a service or an ingredient?” → Need to show how the product really fits into a care + lifestyle pathway.
3. Business model / distribution
The “ingredient + lifestyle service” idea could be explored: for example, a premium ingredient for formulation + a programme for digital monitoring of habits (activity, sleep, etc.). Is this a viable channel? You sell to B2B brands: can they add a service component to their offerings? Counter-argument: Food brands may not want to get involved in prescribing treatments or in the medical interface. You need to clearly define the boundary between “ingredient” and “medicine”.
4. Reality on the ground
Think about the figures: 63,000+ subjects, but a very specific population (veterans). The ROI for a B2B player must take into account the variability of the actual population (male/female mix, ethnicities, comorbidities). Also: monitor the move towards peer-review publication, because without this the message remains “preliminary”.
Conclusion
This study shows that for patients with type 2 diabetes, the «modern drugs (GLP-1 RA) + multiple lifestyle changes» combination» generates a substantial reduction in cardiovascular events. For a professional in the ingredients/health sector: this is a strong signal: your innovations are no longer just “nutrient vs disease” but “nutrient + active life path”.
All that remains is to translate this concept into a clear, validated and credible value proposition.
FAQ - Anti-diabetic drugs and lifestyle: the winning duo for the heart
Q1. What is the main conclusion of the study presented at AHA 2025?
In people with type 2 diabetes, the combination of treatment with GLP-1 receptor agonists and the adoption of at least six healthy lifestyle habits reduces by approximately 50 % the risk of major cardiovascular events compared with those who had neither treatment nor a healthy lifestyle.
Q2. Does this mean that GLP-1 drugs are ineffective without lifestyle changes?
No. GLP-1 receptor agonists already reduce cardiovascular risk by approximately 20 % when used alone.
But their double efficiency when combined with a number of healthy lifestyle habits.
Q3. What are the limitations of this study?
- It's a observational study, So it shows correlation, not causation.
- The population is very specific: American veterans, mostly white men (≈ 94 %).
- The results come from a conference presentations, not yet published in a peer-reviewed scientific journal.
These factors limit the scope of our conclusions.
Q4. What should those involved in health or nutritional ingredients remember?
This study shows that therapeutic efficacy is now dependent on a integrated “medication + lifestyle” approach”.
Ingredients, clinical nutrition and nutraceutical companies can use this trend to position their products as additional and not as substitutes.
The key: scientific credibility, regulatory clarity and consistency with public health messages.